特瑞普利单抗相关不良反应文献分析  

Literature analysis of adverse drug reactions induced by toripalimab

作　　者：杨学斌 刘媛媛[1] 王新[1] 冀召帅 艾超 YANG Xue-bin;LIU Yuan-yuan;WANG Xin;JI Zhao-shuai;AI Chao(Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing 102218)

机构地区：[1]清华大学附属北京清华长庚医院,清华大学临床医学院,北京102218

出　　处：《中南药学》2022年第3期707-712,共6页Central South Pharmacy

基　　金：北京清华长庚医院研究资金(No.12017C1001)。

摘　　要：目的探讨特瑞普利单抗引起药品不良反应(ADR)的特点,为临床用药安全提供参考。方法检索中国知网、万方、维普、PubMed、ScienceDirect和Embase数据库(截至2021年8月),收集关于特瑞普利单抗相关ADR的个案报道,对纳入病例的临床资料、特瑞普利单抗用药情况、ADR的临床表现、名称、发生时间、处置及转归等进行统计分析。结果纳入特瑞普利单抗致ADR的个案报道14篇,共计16例患者,其中男性7例,女性9例;年龄在36~82岁,平均年龄为(56.56±13.74)岁,其中40岁以上患者较多,共14例。ADR发生时间多为2个用药周期后,以心脏毒性(6例)和甲状腺垂体功能异常(4例)为主。经对症治疗后,15例患者好转,1例患者死亡。结论应加强对临床中特瑞普利单抗相关不良反应的关注,以提高临床用药安全性。Objective To determine the characteristics of adverse drug reactions(ADR)induced by toripalimab and provide reference for clinic medication safety.Methods ADRs induced by toripalimab reported in domestic and foreign databases of CNKI,Wanfang,VIP,PubMed,ScienceDirect,and Embase(up to August 2021)were collected.Statistical analysis was conducted on the clinical data of patients and the data of ADRs.Results Totally 14 papers of ADRs induced by toripalimab were included,involving 16 patients(7 males and 9 females).The age ranged from 36 to 82 years,average age was(56.56±13.74)years,with 14 patients over 40 years old.Most ADRs occurred after 2 cycles of medication,mainly including cardiotoxicity in 6 patients and abnormal pituitary function in 4 patients.After symptomatic treatment,15 patients improved and 1 patient died.Conclusion Attention should be paid to ADRs by toripalimab in clinical practice.

关 键 词：特瑞普利单抗 PD-1/PD-L1抑制剂 不良反应 

分 类 号：R969.3[医药卫生—药理学]